Research Article

A Novel Mouse Model of Alzheimer’s Disease with Chronic Estrogen Deficiency Leads to Glial Cell Activation and Hypertrophy

Annik Prat,1 Maik Behrendt,2 Edwige Marcinkiewicz,1 Sebastien Boridy,2 Ram M. Sairam,3,4,5,6 Nabil G. Seidah,1 and Dusica Maysinger2

1 Laboratory of Biochemical Neuroendocrinology, Clinical Research Institute of Montreal, 110 Pine Avenue West, Montreal, QC, Canada H2W 1R7
2 Department of Pharmacology and Therapeutics, McGill University, 3655 Promenade Sir-William-Osler, Room 1314, McIntyre Medical Sciences Building, Montreal, QC, Canada H3G 1Y6
3 Molecular Endocrinology Laboratory, Clinical Research Institute of Montreal, QC, Canada
4 Département de Médecine, Université de Montréal, Montréal, QC, Canada
5 Department of Medicine, Division of Experimental Medicine, Montreal, QC, Canada
6 Department of Physiology, McGill University, Montreal, QC, Canada

Correspondence should be addressed to Nabil G. Seidah, seidahn@ircm.qc.ca and Dusica Maysinger, dusica.maysinger@mcgill.ca

Received 23 March 2011; Revised 14 July 2011; Accepted 15 July 2011

1. Introduction

In the brain, estradiol is formed in neurons and a subpopulation of astrocytes by aromatase-mediated conversion of precursor androgens [1]. Estrogen deficiency was reported to accelerate β-amyloid (Aβ) plaque formation in an Alzheimer’s disease (AD) mouse model combining an aromatase deficiency and an APP23 transgene [2]. There was no significant difference between the estrogen levels in APP23 and wild-type mice independent of age (3, 6, and 12 months); however, the estrogen levels in the brains of APP23-aromatase knockout mice were significantly reduced compared to age-matched ovariectomized APP23 mice. Furthermore, microglial cultures prepared from the brains of these APP23 mice showed impaired Aβ clearance and/or degradation [2].

Another model of estrogen imbalance was provided by follicle-stimulating hormone receptor (FSHR) knockout (FORKO) mice [3]. Our earlier studies showed that homozygous females were infertile, whereas males exhibited reduced fertility [4]. Similarly, inactivating mutations in the FSHR gene in women cause absolute infertility and amenorrhea.
Young and aged FORKO mice exhibit several biochemical and morphological abnormalities in the CNS, including mislocalization of chaperones and mitogen activated kinases, and hypertrophy of astrocytes, especially in aged mice [6–8]. These mice also develop metabolic syndrome [9] and cardiovascular abnormalities, which are risk factors for AD and other neurodegenerative disorders [10–13]. Although several studies indicated the contribution of reduced estrogens in circulation to the AD pathology, the role of this peripheral estrogen pool is still disputed [14–17]. The role of the local (brain) deficit of neuroestrogens is considered to be a critical player leading to CNS impairment associated with mild cognitive impairment (MCI) and AD in women [18–20].

Different studies suggest estrogens as anti-inflammatory agents [21, 22] and powerful modulators of glial cells [23, 24]. Depending on their activation states, microglia exhibit both neuroprotective (weakly activated) [25–27] and destructive (hyperactivated) roles [28–31]. Their role in inflammatory processes may affect AD development [32, 33]. Indeed, epidemiological studies reported that the use of non-steroidal anti-inflammatory drugs could reduce the risk of AD [22, 34, 35]. However, activated resident microglia in a hypoestrogenic environment were unable to effectively clear Aβ deposits and possibly contributed to Aβ oligomerization [2, 36]. Although the internalization of Aβ is not limited to microglia, as both astrocytes and neurons are capable of uptake, microglia are the most efficient at this process in addition to retaining the capacity to degrade Aβ [37].

Several mouse models overexpress human amyloid precursor protein (APP) with and without mutations were generated [38]. These mice developed amyloid plaques in different numbers, usually not before 6–9 months of age. Mouse models expressing APPsw (Swedish mutation) did not develop extensive amyloid aggregation before 18 months of age [39, 40]. However, double transgenic mice APPsw/PS1Δ9 (presenilin-1 lacking exon 9) exhibited elevated Aβ-leveled at 6 months of age and extensive extracellular Aβ-deposits in the cortex and hippocampus at 9–12 months [40].

The objective of this study was to examine the impact of chronic hormone imbalance due to FSHR gene inactivation in the above APPsw/PS1Δ9 mouse model on the development of cortical and hippocampal plaque pathology and glial cell morphology. Accordingly, FSHR knockout (FORKO) mice with targeted disruption of the FSHR gene [3] were bred with the APPsw/PS1Δ9 line. In APPsw/PS1Δ9 and FORKO-APPsw/PS1Δ9 mice, plaques appeared as early as 3 months of age. Although their number did not differ significantly from the APPsw/PS1Δ9 mice later in life, FORKO-APPsw/PS1Δ9 mice exhibited significantly larger and more diffuse plaques in cortical and hippocampal regions. Moreover, enhancement of glial cell recruitment, size, and activation was seen as early as 3 months of age, as revealed by immunohistochemical labeling for both astrocytes and microglia. We further show that treatment of wild-type hippocampal primary cultures with the aromatase inhibitor, letrozole, also leads to glial cell hypertrophy and activation, suggesting that early changes in microglia and astrocytes may contribute to the progression of AD under conditions of local estrogen deficiency.

2. Materials and Methods

2.1. Mouse Strains. FORKO (Fshr−/−) males were produced by interbreeding 129T2/SV EmsJ Fshr+/− males and females [3, 4] and were then crossed with double transgenic females (C3He × C57BL/6) F1 hybrid background). The two transgenes, APPsw and PS1Δ9, were previously described [39–41]. Both are expressed under the control of the mouse prion protein (PrP) promoter and are thus highly expressed in brain neurons and astrocytes. They were obtained by replacement of the PrP open reading frame and their structure is summarized in Figure 1 and its legend. F1 mice (Fshr+/−) were intercrossed. F2 Fshr+/+ mice were intercrossed, while Fshr−/− males were crossed with Fshr+/− females (Fshr−/− females are sterile). Only the male or the two females of each breeding were positive for the 2 transgenes. F3 mice positive for the two transgenes and either Fshr+/+ (1 out of 4) or Fshr−/− (1 out of 4) were analyzed. They were derived from 3 and 4 different breedings, respectively.

2.2. Genotyping. Genomic DNA from the tails of 3-week-old mice was extracted and tested by PCR amplification for the presence of the two transgenes, APPsw and PS1Δ9, and the genotype at the Fshr locus. The wild-type PrP gene and APPsw transgene were detected simultaneously using two specific sense primers, 5′-AACCTCATGTTGGTAGTGG and 5′-GATCTCTGAATGTAATGAG, respectively, and a common antisense primer, 5′-GCAAATTAGGAGACCATCCTTAC. The combination of the 3 primers generated 645 and 420 bp products corresponding to the PrP wild-type allele (internal control) and APPsw transgene, respectively. Similarly, 3 primers were used to detect the wild-type PrP gene and the PS1Δ9 transgene. Two specific sense primers, 5′-AGCAACCGAAGAACTTCGT and 5′-GTTCGAGAATGTGATGG, and a common reverse primer, 5′-AGCAAGCAACTGGTGCTACT, generated 450 and 568 bp products for the PrP gene and PS1Δ9 transgene, respectively. Finally, wild-type Fshr+/+ alleles were detected using the sense 5′-AGTTCAATGGCGTTCCG and antisense 5′-CATGTGATAGTCATGATGG and a common reverse primer, 5′-AGCAAGCAACTGGTGCTACT, generated 450 and 568 bp products for the PrP gene and PS1Δ9 transgene, respectively. Finally, wild-type Fshr−/− alleles were detected using neomycin-specific primers, sense 5′-AAGGGACGTGGCTGTTAG and antisense 5′-AGAAAAGCCGGCCATTTTTG, to generate a 348 bp product.

2.3. Immunohistochemistry. Female mice were sacrificed at 3 or 6 months and brains were dissected. One half of each brain was frozen in isopentane at −35°C and kept at −80°C. A second half was fixed by immersion in 4% formaldehyde for 24 hrs, embedded in paraffin and sectioned into 5 μm thick sections. Cryosections (10 μm), obtained from the frozen half-brains, were fixed in 4% paraformaldehyde for 1 hr, washed in PBS, and incubated with rabbit antibodies directed against GFAP (AB5804; Chemicon International, Temecula, Calif, USA) or Iba1 (Wako Chemicals USA, Richmond, Va, USA) at 1: 400 and 1: 200 dilutions in 1% goat normal serum in PBS, respectively. GFAP labeling was revealed using the ImmunoCruz staining system (Santa Cruz, Calif, USA).
2.4. Image Analysis for Plaques and Glia Quantification. Immunostained sections were analyzed by means of an Olympus BX51 microscope, equipped with motorized stage and focus coupled by means of a CCD camera to a MCID Elite Image analysis system (Imaging Research Inc. St. Catherine, ON, Canada) according to the procedure described by Bell et al. [42, 43]. In summary, the total number of pixels in one field was taken as 1.0, and all immunofluorescent pixels from GFAP or Iba1 staining were taken as % of the total. Photomicrophotographs were collected from four to six sections per animal (n = 5–7 per experimental group). The use of preset shape was not desirable as plaques are not always symmetrical or uniform in size. To maintain consistency and determine plaque size, the outer border of the plaque was traced by the same individual. Plaque sizes were determined as perimeters or total surfaces, and mean values ± SD were calculated for all plaques within the same size range for the selected brain structures in both genotypes.

2.5. Primary Hippocampal Neural Cultures. Primary hippocampal neurons and glia from 5-day-old mouse pups (C57BL/6; background of both the FORKO and APPsw/PS1Δ9) were isolated, mechanically and enzymatically dissociated, counted and seeded (5 × 10^4 cells/well) onto collagen-coated glass cover slips, and grown in a 24-well cell culture plate (Corning) at 37°C and 5% CO₂ initially in phenol-free Dulbecco’s Modified Eagle’s Medium (Invitrogen) with 1 mM L-Glutamine (Sigma), sodium pyruvate, and penicillin-streptomycin-neomycin antibiotic cocktail (Invitrogen). On the second day in vitro, cells are cultured in Neurobasal A medium without phenol red (Invitrogen) supplemented with 2% (v/v) B-27 supplement (Invitrogen), 1% (v/v) penicillin-streptomycin-neomycin PSN (Invitrogen), and 1 mM L-Glutamine (Sigma). Cells were treated on day 5 in vitro with letrozole (1 μM) for 24 hrs.

2.6. 3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyl Tetrazolium Bromide (MTT) Assay. After various time intervals, 50 μl of phosphate buffer saline (PBS; pH 7.2) containing MTT (5 mg/mL) was added to each well, resulting in a final MTT concentration of 0.5 mg/mL. Cells were incubated at 37°C with 5% CO₂ and >95% relative humidity for 180 min, after which media was removed. DMSO was added to lyse the cells and dissolve the formazan produced. Triplicates from each well were collected into a 96-well plate (Sarstedt) and the absorbance at 595 nm of each well was measured using a Benchmark microplate reader (Bio-Rad, Mississauga, ON, Canada). Data was tabulated and graphed using Microsoft Excel 2007.

2.7. Immunocytochemistry. Following treatment, cells were fixed in 4% paraformaldehyde for 15 min at room temperature (RT), followed by three washes for 5 min each with phosphate buffer saline (PBS, pH 7.2); the samples were permeabilized with 0.1% triton-X-100 at RT for 5 min, followed again by three washes in PBS. Nonspecific binding sites were blocked for 60 min at RT with 10% goat serum.
(Sigma) diluted in PBS. The samples were then incubated overnight at 4°C with the primary antibodies (Rat anti-
macII, 1:500 gift from collaborator; rabbit anti-GFAP, 1:250, DakoCytomation; mouse anti-βIII-tubulin, 1:100, Chemicon). Following the incubation, samples were washed three times in PBS and incubated for 60 min at RT with the secondary antibodies (antirat Rhodamine red, 1:500, Jackson Laboratories; antirabbit AlexaFluor 594, 1:1000, Molecular Probes; antimouse AlexaFluor 594, 1:1000, Molecular Probes). Following these three rinses in PBS, the samples were counterstained with Hoechst 33258 (Molecular Probes), rinsed once with distilled water, and mounted onto glass slides using Aqua-Poly/Mount (Polysciences). Fluorescence images were acquired at 63x with a Leica DFC350FX monochrome digital camera connected to a Leica DMI4000B inverted fluorescence microscope. Images were acquired and pseudocolored using Leica Application Suite (LAS) software.

2.8. Statistical Analysis. All data were expressed as mean SEM and analyzed by one-way ANOVA. When a significant effect was obtained with one-way ANOVA, student’s t-test was used for analyzing the significance of the difference between two means. To test for interactions between genotype and gender for each behavioral paradigm, two-way factorial ANOVA was employed. A P value < 0.05 was considered to be statistically significant, unless stated otherwise.

3. Results

3.1. Generation of the Mouse Model FORKO-APPsw/PS1Δ9. To analyze the impact of reduced estrogens on AD development, we generated mice carrying the APPsw and PS1Δ9 transgenes in either a wild type or FORKO background (Figure 1). For this, double transgenic APPsw/PS1Δ9 females exhibiting increased production of both Aβ40/42 peptides [40] were crossed with FORKO males [3]. In all the mice analyzed, the transgenes were kept at the heterozygote level to avoid any phenotype related to their insertion site in the genome. In view of the sterility of FORKO females, the high incidence of lost litters, and the need to select for alleles of three loci, a large number of crossings were required over three generations, representing four years of work, to obtain sufficient mice for the present study (see section 2). The FORKO-APPsw/PS1Δ9 mice did not show marked phenotypic differences from the parental lines, FORKO or APPsw/PS1Δ9, up to at least 6 months of age.

3.2. Analysis of Amyloid Plaque Deposits in APPsw/PS1Δ9 and FORKO-APPsw/PS1Δ9 Mice. Mouse models with varying APP mutations have not shown very extensive amyloid aggregation before 18 months of age [39, 40]. Studies of the double transgenic APPsw/PS1Δ9 mice provided evidence for elevated Aβ-levels in 6-month-old mice, but extensive extracellular Aβ-deposits in the cortex and hippocampus were described in 9–12-month-old mice [40]. We focused on 6-month-old mice, as this period corresponds to an early stage in disease development. The nature of deposits in APPsw/PS1Δ9 mice and the FORKO-APPsw/PS1Δ9 mice was assessed by staining sagital sections with a rabbit polyclonal antibody FCA18, which recognizes both Aβ40 and Aβ42 [45], as well as with Aβ40 (CT40) - and Aβ42 (CT42)-specific antibodies (Figure 2(a)). There was no significant difference in the number of plaques revealed by the FCA18, CT40, or CT42 antibodies, as seen by the quantification in Figure 2(a). However, upon careful examination of the plaques using FCA18 antibodies we noted a marked difference in sizes and compactness (or density) of the immunopositive plaques (Figure 2(b) and Supplementary Figure 1 in Supplementary Material available online at doi: 10.4061/2011/251517). Both mouse strains have a large number of Aβ-aggregates in the frontal association cortex (Figure 2(b), (A) and (B)), as well as in the medial and lateral parietal sensory cortex (Figure 2(b), (C) and (D)) and the hippocampus (Figure 2(b), (E) and (F)). However, the perimeters of the plaques found in the brains of FORKO-APPsw/PS1Δ9 are significantly larger and less dense, as revealed by the staining pattern, in comparison with APPsw/PS1Δ9 transgenic mice, concurring with observations from Borchelt et al. [40]. Quantitative data regarding the image analyses of immunoreactive plaques are presented in pie charts and clearly show plaques in cortical regions with larger perimeters (17% of plaques >200 um) in FORKO-APPsw/PS1Δ9 than in APPsw/PS1Δ9 littermates (2% of plaques >200 um). These differences were not noticeable at 3 months of age given the relatively sparse deposition of plaques in both transgenic mouse strains (data not shown).

Aside from the brain regions in which plaque formation was commonly detected (i.e., cortex and hippocampus) in the APPsw/PS1Δ9 and FORKO-APPsw/PS1Δ9 mice, amyloid deposits develop in the olfactory bulb and occipital lobe (Supplementary Figure 2). Interestingly, even subcortical areas like the cerebellum, a brain region mainly considered to be devoid of Aβ-aggregates in most other animal models [46], had a low number of small size plaques (Supplementary Figure 2, (i)–(l)).

3.3. Astrocyte Hypertrophy and Microglial Activation. Immunostaining with antibodies against GFAP and Iba1/Mac II was used to assess the morphology of astrocytes and microglia in FORKO-APPsw/PS1Δ9 and in APPsw/PS1Δ9. At 6 months of age, there were no marked differences between the two genotypes: (i) GFAP-positive astroglia were enlarged and abundant in FORKO-APPsw/PS1Δ9 mice and in APPsw/PS1Δ9 mice (Figure 3), and (ii) Iba1/MacII-positive microglia were also enlarged and exhibited morphologies reminiscent of highly activated states. Differences between the strains at 3 months of age were not apparent either (Figures 3(a), (A) and (B) and 3(b), (A) and (B)).

Multiple attempts to set primary neural cortical and hippocampal cultures from FORKO-APPsw/PS1Δ9 mice failed because the cells from these chimeric mice detached within 24–30 hours, whereas the same conditions were suitable for control cultures with similar genetic background (C57BL6). Interestingly, while performing brain dissection for primary cultures, the brains of chimeric mice appeared less structured and less solid suggesting that connections between neural
Figure 2: Six-month-old sex-hormone-imbalanced FORKO-APPsw/PS1Δ9 mice show similar plaque localization and number but difference in plaque appearance and size compared to mice coexpressing APPsw/PS1Δ9 alone. (a) Six-month-old sex-hormone-imbalanced FORKO-APPsw/PS1Δ9 mice show no significant changes in plaques number compared to mice coexpressing APPsw/PS1Δ9 alone. APPsw/PS1Δ9 and FORKO-APPsw/PS1Δ9 mice were examined by immunocytochemical staining for Aβ peptide with the polyclonal antibody anti-Aβ40/42 (FCA18), anti-Aβ40 (CT40), or anti-Aβ42 (CT42). Quantification of plaques number was achieved by plaque counting on sagittal brain sections of hippocampus and cortex in APPsw/PS1Δ9 (+/+; n = 6) and FORKO-APPsw/PS1Δ9 (−/−; n = 6). (b) Presented is anti-Aβ40/42 (FCA18) immunostaining of sagittal brain sections from APPsw/PS1Δ9 (n = 6; (A), (C), and (E)) and FORKO-APPsw/PS1Δ9 (n = 6; (B), (D), and (F)). By 6 months of age, both mice strains had developed Aβ plaques in typical areas of the brain, such as ((A) and (B)) the frontal cortex, ((C) and (D)) the parietal cortex, and ((E) and (F)) the hippocampus. Note that many more relatively large and diffuse plaques are found in chimeric mice compared to those in APPsw/PS1Δ9 brains. Scale bar in all panels is 20 µm. (G) Quantification of the plaques perimeter revealed 16.67% of large, 17.54 % of medium, and 65.79 % of small plaques in FORKO-APPsw/PS1Δ9 (H) compared to 2.3% of large plaques, 14.94% of medium and 82.76% of small plaques in APPsw/PS1Δ9 (G).
Figure 3: Sex-hormone-imbalanced 6-month-old FORKO-APPsw/PS1Δ9 mice show enhanced number and hypertrophy of astrocytes and microglia in the vicinity of plaques in the hippocampus. Immunostaining for astrocytes and microglia was performed in representative areas of the cortex using polyclonal antibodies for GFAP (a) and MacII in (b) in APPsw/PS1Δ9 mice and FORKO-APPsw/PS1Δ9. Note that astroglia and microglia show an enlargement and increase in number, suggesting glial activation and inflammation in both APPsw/PS1Δ9 FORKO-APPsw/PS1Δ9 mice, more strikingly in the latter model. Scale bar measures 50 μm.
cells were reduced in these brains. Therefore, we used primary hippocampal dispersed cultures from wild-type mice and exposed them to letrozole, an aromatase inhibitor, for 24 hrs to assess the changes in the neural cells with suppressed estrogen synthesis. Hippocampal neural cells treated with 10^{-6} M letrozole stably attached to the plastic surface, exhibiting similar viability to control cultures (Supplementary Figure 3). Morphological changes in glial state and neurons in this in vitro model are shown (Figures 4(a) and 4(b)). BIII-tubulin-positive letrozole-treated neurons exhibited significant enlargement of their processes compared to the control (Figure 4(a), (A) and (B)), while highly activated microglia showed increased immunoreactivity for mac-2 following letrozole treatment (Figure 4(a), (E) and (F)) and GFAP-immunopositive astrocytes were significantly larger in letrozole treated cells compared with untreated controls (Figure 4(a), (C) and (D)), as confirmed by quantitative analysis (Figure 4(b)).

Given that metabolic dysfunction and oxidative stress are early events in AD [33, 47, 48] and that many of the neuroprotective effects of estrogens have been attributed to rescue of mitochondrial function [49] we also decided to investigate mitochondrial status following estrogen deprivation. In primary hippocampal neural cultures with and without letrozole treatment for 24 hrs, we labeled mitochondria using MitoTracker Deep Red 633 (Figure 4 G-H). Images captured with confocal microscopy reveal significant mitochondrial fragmentation and loss following letrozole treatment, which has been shown to correlate with a state of mitochondrial and synaptic dysfunction in the CNS [50].

4. Discussion

Estrogens in the CNS play both neuroprotective and neuromodulatory roles [51–53], which was associated with the increased incidence of age-related neurodegenerative diseases in women [54, 55]. The controversies over the concentrations of peripheral and brain sex hormones in cases with mild cognitive impairments (MCI) and AD are still not resolved [15, 17, 56–58]. Several clinical trials are ongoing and the results confirming or refuting the role of declining endogenous estradiol and effectiveness of hormone replacement therapy in early or even undiagnosed AD are eagerly awaited.

Results from our studies present a new mouse model with three mutated loci (FORKO/APPsw/PS1Δ9), conferring sex hormone imbalance and AD pathology. The results clearly show that FORKO-APPsw/PS1Δ9 mice have larger and more diffuse plaques than the double transgenic model, in addition to significant hypertrophy and activation of microglia and astrocytes, corroborating findings that estrogens are potent glia regulators [17, 22, 59, 60] whose state may be either beneficial or destructive in the CNS [61], particularly in aging.

FORKO females exhibit hypergonadotropic-hypogonadism with high levels of circulating FSH and LH similar to the postmenopausal state in women [62]. In menopause, dramatic and rapidly occurring cessation of gonadal function leads to a loss of estrogens in women around 51 years of age [44, 63]. In contrast to menopause in women, men do not experience irreversible arrest of reproductive capacity in old age and aging in men is characterized by a gradual and slow decline in testosterone with half bioavailable testosterone levels at 75 years of age relative to younger men [64, 65]. Consequent to gender differences in senescence, significant differences are also found in the incidence, timing, and susceptibility of age-related conditions, such as osteoporosis, obesity, cardiovascular diseases, type 2 diabetes, depression, anxiety, insomnia, and memory impairment [44, 63, 64, 66–76].

Results from the triple mutant mouse model FORKO/APPsw/PS1Δ9 presented here support the notion that the reduced circulating levels of estradiol do not significantly contribute to the plaque numbers but rather influence their compactness and size. Moreover, subphysiological concentrations of estrogens in this mouse model of Alzheimer’s disease (FORKO/APPsw/PS1Δ9) show significant reactivity of both astrocytes and microglia.

Both glia and neurons can synthesize estrogens in human and rodent brains. The synthesis is catalyzed by the enzyme aromatase, widely distributed in the brain regions including those affected in AD, for example, basal forebrain, cerebral cortex, and hippocampus [1]. Although the positron emission tomography of human subjects has given us some insight into the general map of the human aromatase expression, the detailed distribution map still remains to be completed. Several studies point towards the significance of the local production of estradiol by aromatase conversion of testosterone in the brain, particularly on the neurons in the hippocampus [1, 16, 20, 77, 78]. Moreover, estrogens exert inhibitory effects on inflammation as well as, microglial and astroglial activation in several brain regions including cerebral cortex and hippocampus [22, 26, 59, 60, 79, 80]. Specifically, estrogen downregulates the release of inducible nitric oxide synthase (iNOS), tumour necrosis factor alpha (TNFα), interleukin-6 (IL-6), and interferon-gamma inducible protein-10 (IP-10) in cultured astrocytes activated with lipopolysaccharide (LPS) [81, 82]. Moreover, it was shown previously that long-term estrogen deprivation accelerates the appearance of highly reactive microglia at amyloid deposits, an event that was prevented by estradiol replacement [22].

The link between inflammation, microglia, and AD pathology was proposed long ago [34], but studies investigating the origin of microglia associated with plaques in AD are more recent and bring out different observations [83–85]. Microglia are attracted to the region surrounding senile plaques in human and rodent tissues [86–92] and Aβ40 and Aβ42 isoforms serve as chemoattractants. Conversely, chronic inflammation of the central nervous system associated with hyperactive states of glial cells is a risk factor for AD. We did not explore the origin of microglia but we show that they play a role in determining the size and shape of plaques in both APPsw/PS1Δ9 mice and in the FORKO-APPsw/PS1Δ9 mice. Importantly, this diffuse plaque state created by activated microglia unable to efficiently clear Aβ aggregates may lead to the release of soluble forms of Aβ from...
Figure 4: Immunocytochemical assessment of neuronal and glial status in primary hippocampal cultures treated with letrozole. Primary dissociated hippocampal cultures were treated with letrozole (1 µM, 24 hrs), following which immunocytochemical analysis was performed for cell-specific markers. (a) Neurons ((A) and (B)) were stained with antibodies against beta III tubulin (1 : 100), astrocytes ((C) and (D)) with anti-GFAP (1 : 500), and microglia ((E) and (F)) with anti-Mac-2 (1 : 350). Note the marked astrocyte hypertrophy in letrozole-treated cells. Arrowheads indicate enlargement of the neuronal processes following Lz treatment. Arrows in (F) outline activated microglia, which exhibit increased mac-2 staining. ((G) and (H)) MitoTracker Deep Red 633 staining revealed truncated mitochondria in Lz-treated cells compared with control, indicative of increased mitochondrial fission and potentially mitochondrial dysfunction. Scale bar (20 µm) in first panel is representative for all panels. (b) Quantification of stained area per cell for neurons (βIII-tubulin), astrocytes (GFAP), and microglia (mac-2) following letrozole treatment.

To address the question of astrocyte hypertrophy and microglia activation in states of reduced estradiol synthesis by neural cells, we performed experiments with primary cultures. Dispersed primary hippocampal and cortical cultures from the brains of FORKO-APPsw/PS1Δ9 were not viable, therefore, for in vitro studies, we used wild-type mice and a common pharmacological approach to reduce estradiol synthesis using letrozole which inhibits aromatase enzymatic activity [16, 77]. Primary dissociated hippocampal cultures
treated with letrozole show marked glial hypertrophy and microglial activation suggesting that such cultures could be useful for screening new therapies for neurological disorders accompanied by gliopathies in hypoestrogenic states. Our results show mac-2-positive staining in the hippocampus of chimeric mice, a marker of activated microglia, which is in accordance with the observation of mac-2 upregulation in wild-type cultures with pharmacologically inhibited aromatase by letrozole, previously used to study synaptic plasticity in hippocampal primary cultures [16, 77, 78, 98]. This experimental paradigm also allowed an assessment of mitochondrial morphological and functional status in neural cells, given that mitochondria respond to estradiol treatment [49].

Mitochondria are organelles known to be affected in AD [99]. It was reported that impairments in mitochondrial fission and fusion can lead to mitochondrial dysfunction and synaptic deficits in AD [100, 101]. Estradiol acts through mitochondria to exhibit neuroprotection. Our finding that estradiol deprivation leads to mitochondrial fragmentation and loss is not surprising, but it is among the first to show a correlation between glial activation and mitochondrial fragmentation in states of estrogen deprivation and sex-hormone imbalance. These observations suggest that estrogen may modulate mitochondria to regulate glial cell activation and hypertrophy.

In summary, results from the present study support the notion that activated glia in a hypoestrogenic state could potentiate the effects of inflammation, in addition to enhancing Aβ release from plaques, and Aβ oligomerization. These forms of Aβ are major soluble neurotoxicants [102], therefore it is plausible that in the aged chimeric brains, cell loss could be due to enhanced oligomer formation. Results from the pilot studies indicate that the levels of Aβ in the brain of chimeric mice are not significantly different from APPsw/PS1Δ9, but the kinetics of Aβ monomer and soluble oligomer formation remains to be determined. In order to detect and quantify small differences between these two genotypes with limited CSF and blood samples, we are currently developing nanobased sensors which could enable measurements of Aβ monomers and oligomers in small volumes of these biological samples.

In addition, results from our chimeric FORKO/APPsw/PS1Δ9 mouse model are in line with both the Brinton hypothesis [103, 104] and the critical window hypothesis [105]. Although the two interrelated hypotheses, for example, (1) healthy cell bias of gonadal hormone action hypothesis [103, 104] and (2) the critical window hypothesis [105], reconcile previous controversies, they do not yet explain the positive versus negative effects of estrogens on cognition. Ongoing clinical studies with initiated estrogen therapy in young women, together with mechanistic investigations, will provide new insights to resolve the controversial issues. Our studies are also in line with elegant work by García-Segura’s group suggesting that the brain aromatase in the central nervous system and the local production of estradiol in the brain play a critical role in maintaining normal physiological central nervous system functions, including those in neurons and glial cells affected in AD [59, 79]. A particularly attractive feature of future studies is to explore the selective estrogen receptor modulators to normalize hyperactive glial cells and the release of proinflammatory cytokines and chemokines in inflammation, not only in AD, but also in other neurological disorders accompanied by excessive gliosis [80].

Conflict of Interests

None of the authors have any actual or potential conflict of interests with other people or organizations that could influence this work.

Acknowledgments

The authors would like to acknowledge the generous gift of the double transgenic APPsw/PS1Δ9 mice from Dr. D. R. Borchelt, Johns Hopkins University, USA. They would like to thank Dr. Martin Markiewicz for his help and advice. The secretarial assistance of Mrs. Brigitte Mary is greatly appreciated. This work was supported in part by Alzheimer’s Association USA (IIRG-05-1352), the Canadian Institutes of Health Research (CIHR, no. MOP-142626, no.MOP-49516) to Dusica Maysinger and Nabil G. Seidah. Annik Prat and Maik Behrendt contributed equally to this study.

References

[1] I. Azcoitia, J. G. Yague, and L. M. Garcia-Segura, “Estradiol synthesis within the human brain,” Neuroscience, vol. 191, pp. 139–147, 2011.
[2] X. Yue, M. Lu, T. Lancaster et al., “Brain estrogen deficiency accelerates Aβ plaque formation in an Alzheimer’s disease animal model,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 52, pp. 19198–19203, 2005.
[3] A. Dierich, M. R. Sairam, L. Monaco et al., “Impairing follicle-stimulating hormone (FSH) signaling in vivo: targeted disruption of the FSH receptor leads to aberrant gametogenesis and hormonal imbalance,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 23, pp. 13612–13617, 1998.
[4] H. Krishnamurthy, R. Kats, N. Danilovich, D. Javeshgani, and M. R. Sairam, “Intercellular communication between Sertoli cells and Leydig cells in the absence of follicle-stimulating hormone-receptor signaling,” Biology of Reproduction, vol. 65, no. 4, pp. 1201–1207, 2001.
[5] C. H. Matthews, S. Borgato, P. Beck-Peccoz et al., “Primary amenorrhea and infertility due to a mutation in the β-subunit of follicle-stimulating hormone,” Nature Genetics, vol. 5, no. 1, pp. 83–86, 1993.
[6] J. Tam, N. Danilovich, K. Nilsson, M. R. Sairam, and D. Maysinger, “Chronic estrogen deficiency leads to molecular aberrations related to neurodegenerative changes in folitroin receptor knockout female mice,” Neuroscience, vol. 114, no. 2, pp. 493–506, 2002.
[7] N. Danilovich, M. R. Sairam, and D. Maysinger, “The menopausal mouse: a new neural paradigm of a distressing human condition,” NeuroReport, vol. 14, no. 12, pp. 1617–1622, 2003.
[8] L. Rumora, J. Lovrić, M. R. Sairam, and D. Maysinger, “Impairments of heat shock protein expression and MAPK
translocation in the central nervous system of follitropin receptor knockout mice," *Experimental Gerontology*, vol. 42, no. 7, pp. 619–628, 2007.

[9] M. R. Sairam, M. Wang, N. Danilovich, D. Javeshghani, and D. Maysinger, "Early obesity and age-related mimicry of metabolic syndrome in female mice with sex hormonal imbalances," *Obesity*, vol. 14, no. 7, pp. 1142–1154, 2006.

[10] N. Danilovich, D. Maysinger, and M. R. Sairam, "Perspectives on reproductive senescence and biological aging: studies in genetically altered follitropin receptor knockout [FORKO] mice," *Experimental Gerontology*, vol. 39, no. 11-12, pp. 1669–1678, 2004.

[11] D. Javeshghani, E. L. Schiffrin, M. R. Sairam, and R. M. Touyz, "Potentiation of vascular oxidative stress and nitric oxide-mediated endothelial dysfunction by high-fat diet in a mouse model of estrogen deficiency and hyperandrogenemia," *Journal of the American Society of Hypertension*, vol. 3, no. 5, pp. 295–305, 2009.

[12] N. R. Bhat, "Linking cardiometabolic disorders to sporadic Alzheimer’s disease: a perspective on potential mechanisms and mediators," *Journal of Neurochemistry*, vol. 115, no. 3, pp. 551–562, 2010.

[13] T. C. de Toledo Ferraz Alves, L. K. Ferreira, M. Wajngarten, and G. F. Busatto, "Cardiac disorders as risk factors for Alzheimer’s disease," *Journal of Alzheimer’s Disease*, vol. 20, no. 3, pp. 749–763, 2010.

[14] E. Hogervorst and S. Bandelow, "The controversy over levels of sex steroids in cases with Alzheimer’s disease," *Journal of Neuroendocrinology*, vol. 16, no. 2, pp. 93–94, 2004.

[15] C. E. Gleason, B. Choleront, C. M. Carlsson, S. C. Johnson, and S. Ashiana, "Neuroprotective effects of female sex steroids in humans: current controversies and future directions," *Cellular and Molecular Life Sciences*, vol. 62, no. 3, pp. 299–312, 2005.

[16] G. M. Rune, C. Lohse, J. Prange-Kiel, L. Fester, and M. Frotscher, "Synaptic plasticity in the hippocampus: effects of estrogen on the gonads or hippocampus?" *Neurochemical Research*, vol. 31, no. 2, pp. 145–155, 2006.

[17] S. N. Alain, D. Bentue-Ferrer, and Y. Akwa, "Treatment of the inflammatory activity in brain: a therapeutic opportunity for menopause and neurodegenerative diseases," *Frontiers in Neuroendocrinology*, vol. 29, no. 4, pp. 507–519, 2008.

[18] K. M. Dhandapani and D. W. Brann, "Role of astrocytes in estrogen-mediated neuroprotection," *Experimental Gerontology*, vol. 42, no. 1-2, pp. 70–75, 2007.

[19] A. Sierra, A. Gottfried-Blackmore, T. A. Milner, B. S. McEwen, and K. Bulloch, "Steroid hormone receptor expression and function in microglia," *Glia*, vol. 56, no. 6, pp. 659–674, 2008.

[20] A. Nimmerjahn, F. Kirchhoff, and F. Helmchen, "Neuroscience: resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo," *Science*, vol. 308, no. 5726, pp. 1314–1318, 2005.

[21] A. R. Simard and S. Rivest, "Neuroprotective effects of resident microglia following acute brain injury," *Journal of Comparative Neurology*, vol. 504, no. 6, pp. 716–729, 2007.

[22] M. B. Graeber, "Changing face of microglia," *Science*, vol. 330, no. 6005, pp. 783–788, 2010.

[23] M. L. Block, L. Zecca, and J. S. Hong, "Microglia-mediated neurotoxicity: uncovering the molecular mechanisms," *Nature Reviews Neuroscience*, vol. 8, no. 1, pp. 57–69, 2007.

[24] M. L. Block, "NADPH oxidase as a therapeutic target in Alzheimer’s disease," *BMC Neuroscience*, vol. 9, supplement 2, article S8, 2008.

[25] M. E. Lall and M. L. Block, "Microglial activation and chronic neurodegeneration," *Neurotherapeutics*, vol. 7, no. 4, pp. 354–365, 2010.

[26] E. G. McGeer and P. L. McGeer, "Neuroinflammation in Alzheimer’s disease and mild cognitive impairment: a field in its infancy," *Journal of Alzheimer’s Disease*, vol. 19, no. 1, pp. 355–361, 2010.

[27] G. Candore, C. R. Balisteri, M. P. Grimaldi et al., "Age-related inflammatory diseases: role of genetics and gender in the pathophysiology of Alzheimer’s disease," *Annals of the New York Academy of Sciences*, vol. 1089, pp. 472–486, 2006.

[28] P. Agostinho, R. A. Cunha, and C. Oliveira, "Neuroinflammation, oxidative stress and the pathogenesis of Alzheimer’s disease," *Current Pharmaceutical Design*, vol. 16, no. 25, pp. 2766–2778, 2010.

[29] P. L. McGeer, M. Schulzer, and E. G. McGeer, "Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer’s disease: a review of 17 epidemiologic studies," *Neurology*, vol. 47, no. 2, pp. 425–432, 1996.

[30] P. L. McGeer and E. G. McGeer, "NSAIDs and Alzheimer disease: epidemiological, animal model and clinical studies," *Neurobiology of Aging*, vol. 28, no. 5, pp. 639–647, 2007.

[31] D. G. Walker and L. F. Luc, "Investigations with cultured human microglia on pathogenic mechanisms of Alzheimer’s disease and other neurodegenerative diseases," *Journal of Neuroscience Research*, vol. 81, no. 3, pp. 412–425, 2005.

[32] S. Mandrekar, Q. Jiang, C. Y. D. Lee, J. Koenigsknecht-Talbou, D. M. Holtzman, and G. E. Landreth, "Microglia mediate the clearance of soluble β through fluid phase macropinocytosis," *Journal of Neuroscience*, vol. 29, no. 13, pp. 4252–4262, 2009.

[33] J. Götz and L. M. Ittner, "Animal models of Alzheimer’s disease and frontotemporal dementia," *Nature Reviews Neuroscience*, vol. 9, no. 7, pp. 532–544, 2008.

[34] D. R. Borchelt, G. Thinakaran, C. B. Eckman et al., "Familial Alzheimer’s disease-linked presenilin 1 variants elevate αβ1-42/1-40 ratio in vitro and in vivo," *Neuron*, vol. 17, no. 5, pp. 1005–1013, 1996.

[35] D. R. Borchelt, T. Ratovitski, J. van Lare et al., "Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor protein," *Neuron*, vol. 19, no. 4, pp. 939–945, 1997.

[36] G. Thinakaran, D. R. Borchelt, M. K. Lee et al., "Endoproteolysis of presenilin 1 and accumulation of processed derivatives in vivo," *Neuron*, vol. 17, no. 1, pp. 181–190, 1996.

[37] K. F. Bell, G. J. de Kort, S. Steggerda, R. Shigemoto, A. Ribeiro-da-Silva, and A. C. Cuello, "Structural involvement
of the glutamatergic presynaptic boutons in a transgenic mouse model expressing early onset amyloid pathology,” *Neuroscience Letters*, vol. 353, no. 2, pp. 143–147, 2003.

[43] K. F. Bell, A. Ducatenzeiler, A. Ribeiro-da-Silva, K. Duff, D. A. Bennett, and A. C. Cuello, “The amyloid pathology progresses in a neurotransmitter-specific manner,” *Neurobiology of Aging*, vol. 27, no. 11, pp. 1644–1657, 2006.

[44] P. M. Wise, “Neuroendocrine modulation of the “menopause”: insights into the aging brain,” *American Journal of Physiology*, vol. 277, no. 6, pp. E965–E970, 1999.

[45] H. Barelli, A. Lebeau, J. Vizzavona et al., “Characterization of new polyclonal antibodies specific for 40 and 42 amino acid-long amyloid β peptides: their use to examine the cell biology of presenilins and the immunohistochemistry of sporadic Alzheimer’s disease and cerebral amyloid angiopathy cases,” *Molecular Medicine*, vol. 3, no. 10, pp. 695–707, 1997.

[46] R. G. Cutler, J. Kelly, K. Storie et al., “Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer’s disease,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 101, no. 7, pp. 2070–2075, 2004.

[47] I. L. Ferreira, R. Resende, E. Ferreiro, A. C. Rego, and C. F. Pereira, “Multiple defects in energy metabolism in Alzheimer’s disease,” *Current Drug Targets*, vol. 11, no. 10, pp. 1193–1206, 2010.

[48] H. Du, L. Guo, S. Yan, A. A. Sosunov, G. M. McKhann, and S. S. Yan, “Early deficits in synaptic mitochondria in an Alzheimer’s disease mouse model,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 107, no. 43, pp. 18670–18675, 2010.

[49] J. W. Simpkins, K. D. Yi, S. H. Yang, and J. A. Dykens, “Mitochondrial mechanisms of estrogen neuroprotection,” *Biochimica et Biophysica Acta*, vol. 1800, no. 10, pp. 1113–1120, 2010.

[50] H.-L. Wang, A.-H. Chou, A.-S. Wu et al., “PARK6 PINK1 mutants are defective in maintaining mitochondrial membrane potential and inhibiting ROS formation of substantia nigra dopaminergic neurons,” *Biochimica et Biophysica Acta*, vol. 1812, no. 6, pp. 674–684, 2011.

[51] D. Manthey and C. Behl, “From structural biochemistry to expression profiling: neuroprotective activities of estrogen,” *Neuroscience*, vol. 138, no. 3, pp. 845–850, 2006.

[52] T. Smejkalova and C. S. Woolley, “Estriadiol acutely potentiates hippocampal excitatory synaptic transmission through a presynaptic mechanism,” *Journal of Neuroscience*, vol. 30, no. 48, pp. 16137–16148, 2010.

[53] J. L. Herrera, C. Fernandez, M. Diaz, D. Cury, and R. Marin, “Estriadiol and tamoxifen differentially regulate a plasmalemal voltage-dependent anion channel involved in amyloid-beta induced neurotoxicity,” *Steroids*, vol. 76, no. 9, pp. 840–844, 2011.

[54] K. F. Manaye, J. S. Allard, S. Kalifa et al., “17alpha-estradiol attenuates neuron lossin ovariectomized Dtg AbetaPP/PS1 mice,” *Journal of Alzheimer’s Disease*, vol. 23, no. 4, pp. 629–639, 2011.

[55] A. Morinaga, K. Ono, J. Takasaki, T. Ikeda, M. Hirohata, and M. Yamada, “Effects of sex hormones on Alzheimer’s disease-associated β-amyloid oligomer formation in vitro,” *Experimental Neurology*, vol. 228, no. 2, pp. 298–302, 2011.

[56] B. B. Sherwin, “Estrogen and cognitive aging in women,” *Trends in Pharmacological Sciences*, vol. 23, no. 11, pp. 527–534, 2002.

[57] R. D. Brinton, “Requirements of a brain selective estrogen: advances and remaining challenges for developing a NeuroSERM,” *Journal of Alzheimer’s Disease*, vol. 6, pp. S27–S35, 2004.

[58] M. C. Craig, P. M. Maki, and D. G. M. Murphy, “The Women’s health initiative memory study: findings and implications for treatment,” *The Lancet Neurology*, vol. 4, no. 3, pp. 190–194, 2005.

[59] M. A. Arevalo, M. Santos-Galindo, M. J. Bellini, I. Arcotita, and L. M. Garcia-Segura, “Actions of estrogens on glial cells: implications for neuroprotection,” *Biochimica et Biophysica Acta*, vol. 1800, no. 10, pp. 1106–1112, 2010.

[60] J. A. Smith, A. Das, J. T. Butler, S. K. Ray, and N. L. Banik, “Estrogen or estrogen receptor agonist inhibits lipopolysaccharide induced microglial activation and death,” *Neurochemical Research*, vol. 36, no. 9, pp. 1587–1593, 2011.

[61] U. K. Hanisch and H. Kettenmann, “Microglia: active sensor and versatile effector cells in the normal and pathologic brain,” *Nature Neuroscience*, vol. 10, no. 11, pp. 1387–1394, 2007.

[62] E. R. te Velde, G. J. Scheffer, M. Dorland, F. J. Broekmans, and B. C. J. M. Fauser, “Developmental and endocrine aspects of normal ovarian aging,” *Molecular and Cellular Endocrinology*, vol. 145, no. 1–2, pp. 67–73, 1998.

[63] F. L. Bellino, “Nonprimate animal models of menopause: workshop report,” *Menopause*, vol. 7, no. 1, pp. 14–24, 2000.

[64] E. E. Baulieu, “On ‘steroid aging’,” *Comptes Rendus Biologies*, vol. 325, no. 6, pp. 747–749, 2002.

[65] A. Novák, M. Brod, and J. Elbers, “Andropause and quality of life: findings from patient focus groups and clinical experts,” *Maturitas*, vol. 43, no. 4, pp. 231–237, 2002.

[66] N. B. Huri, “X-Rays, a vital tool, but use it carefully,” *Dental Student*, vol. 53, no. 9, article 60, 1975.

[67] J. Stepán, J. Pospichal, J. Formanová et al., “Transdermal estradiol in the prevention of the menopause-induced increase in osteoresorption,” *Ceskoslovenska Gynekologie*, vol. 54, no. 7, pp. 496–505, 1989.

[68] V. A. Giagulli, J. M. Kaufman, and A. Vermeulen, “Pathogenesis of the decreased androgen levels in obese men,” *Journal of Clinical Endocrinology and Metabolism*, vol. 79, no. 4, pp. 997–1000, 1994.

[69] S. Nolen-Hoeksema, “The role of rumination in depressive episodes,” *Journal of Abnormal Psychology*, vol. 109, no. 3, pp. 504–511, 2000.

[70] R. L. Roof and E. D. Hall, “Estrogen-related gender difference in survival rate and cortical blood flow after impact-acceleration head injury in rats,” *Journal of Neurotrauma*, vol. 17, no. 12, pp. 1155–1169, 2000.

[71] Y. Takahashi, H. Hohjoh, and K. Matsuura, “Predisposing factors in delayed sleep phase syndrome,” *Psychiatry and Clinical Neurosciences*, vol. 54, no. 3, pp. 356–358, 2000.

[72] B. S. McEwen, “Estrogens effects on the brain: multiple sites and molecular mechanisms,” *Journal of Applied Physiology*, vol. 91, no. 6, pp. 2785–2801, 2001.

[73] R. S. Tan and S. J. Pu, “Impact of obesity on hypogonadism in the andropause,” *International Journal of Andrology*, vol. 25, no. 4, pp. 195–201, 2002.

[74] A. von Eckardstein and F. C. W. Wu, “Testosterone and atherosclerosis,” *Growth Hormone and IGF Research*, vol. 13, pp. S72–S84, 2003.

[75] M. Oettel, D. Hübner, and V. Patchev, “Selected aspects of endocrine pharmacology of the aging male,” *Experimental Gerontology*, vol. 38, no. 1-2, pp. 189–198, 2003.
[76] R. S. Swerdlow and C. Wang, “Androgens and the ageing male,” Best Practice and Research: Clinical Endocrinology and Metabolism, vol. 18, no. 3, pp. 349–362, 2004.

[77] C. von Schassen, L. Fester, J. Prange-Kiel et al., “Oestrogen synthesis in the hippocampus: role in axon outgrowth,” Journal of Neuroendocrinology, vol. 18, no. 11, pp. 847–856, 2006.

[78] L. Zhou, L. Fester, B. von Blittersdorff et al., “Aromatase inhibitors induce spine synapse loss in the hippocampus of ovariecctomized mice,” Endocrinology, vol. 151, no. 3, pp. 1153–1160, 2010.

[79] I. Azcoitia, M. Santos-Galindo, M. A. Arevalo, and L. M. Garcia-Segura, “Role of astroglia in the neuroplastic and neuroprotective actions of estradiol,” European Journal of Neuroscience, vol. 32, no. 12, pp. 1995–2002, 2010.

[80] M. A. Arevalo, Y. Diz-Chaves, M. Santos-Galindo, M. J. Bellini, and L. M. Garcia-Segura, “Selective oestrogen receptor modulators decrease the inflammatory response of Glial Cells,” Journal of Neuroendocrinology, 2011.

[81] M. Tenenbaum, A. N. Azab, and J. Kaplanski, “Effects of estrogen against LPS-induced inflammation and toxicity in primary rat glial and neuronal cultures,” Journal of Endotoxin Research, vol. 13, no. 3, pp. 158–166, 2007.

[82] M. Cerciat, M. Unkila, L. M. Garcia-Segura, and M. A. Arevalo, “Selective estrogen receptor modulators decrease the production of interleukin-6 and interferon-γ-inducible protein-10 by astrocytes exposed to inflammatory challenge in vitro,” Glia, vol. 58, no. 1, pp. 93–102, 2010.

[83] D. C. Hess, T. Abe, W. D. Hill et al., “Hematopoietic origin of microglial and perivascular cells in brain,” Experimental Neurology, vol. 186, no. 2, pp. 134–144, 2004.

[84] A. R. Simard and S. Rivest, “Bone marrow stem cells have the ability to populate the entire central nervous system into fully differentiated parenchymal microglia,” The FASEB Journal, vol. 18, no. 9, pp. 998–1000, 2004.

[85] R. M. Ransohoff and V. H. Perry, “Microglial physiology: unique stimuli, specialized responses,” Annual Review of Immunology, vol. 27, pp. 119–145, 2009.

[86] D. W. Dickson, J. Farlo, P. Davies, H. Crystal, P. Fuld, and S. H. C. Yen, “Alzheimer’s disease. A double-labeling immuno-histochemical study of senile plaques,” American Journal of Pathology, vol. 132, no. 1, pp. 86–101, 1988.

[87] S. Haga, K. Akai, and T. Ishii, “Demonstration of microglial cells in and around senile (neuritic) plaques in the Alzheimer brain. An immunohistochemical study using a novel monoclonal antibody,” Acta Neuropathologica, vol. 77, no. 6, pp. 569–575, 1989.

[88] L. S. Perlmutter, S. A. Scott, E. Barron, and H. C. Chui, “MHC class II-positive microglia in human brain: association with Alzheimer lesions,” Journal of Neuroscience Research, vol. 33, no. 4, pp. 549–558, 1992.

[89] J. Wegiel, H. Imaki, K. C. Wang et al., “Origin and turnover of microglial cells in fibrillar plaques of APPsw transgenic mice,” Acta Neuropathologica, vol. 105, no. 4, pp. 393–402, 2003.

[90] R. G. Nagele, J. Wegiel, V. Venkataraman, H. Imaki, K. C. Wang, and J. Wegiel, “Contribution of glial cells to the development of amyloid plaques in Alzheimer’s disease,” Neurobiology of Aging, vol. 25, no. 5, pp. 663–674, 2004.

[91] T. M. Malm, M. Koistinaho, M. Pårepalo et al., “Bone marrow-derived cells contribute to the recruitment of microglial cells in response to β-amyloid deposition in APP/PS1 double transgenic Alzheimer mice,” Neurobiology of Disease, vol. 18, no. 1, pp. 134–142, 2005.